CAS 332348-12-6

1-25-Oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol. (146->146')-disulfide

Description:

1-25-Oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) fusion protein with immunoglobulin G1 (human heavy chain fragment) is a complex biopharmaceutical designed for therapeutic applications, particularly in immunology and oncology. This fusion protein combines elements of oncostatin M, a cytokine involved in immune regulation, with CTLA-4, a critical immune checkpoint that modulates T-cell activation. The inclusion of an immunoglobulin G1 (IgG1) fragment enhances its stability and half-life in circulation, facilitating prolonged therapeutic effects. The presence of a disulfide bond indicates a specific structural configuration that is crucial for maintaining the protein's integrity and functionality. This compound is typically produced through recombinant DNA technology and is characterized by its ability to modulate immune responses, potentially enhancing anti-tumor activity. Its application may involve the treatment of various cancers or autoimmune diseases, where modulation of the immune system is beneficial. As with many biologics, its efficacy and safety profile would be evaluated through clinical trials before therapeutic use.

Abatacept

CAS: 332348-12-6

Abatacept: soluble CTLA4-IgG1 fusion, T-cell modulator for autoimmune diseases.

Purity: 98%

Color and Shape: Solid

Molecular weight: N/A

Ref: TM-T10218